|
Shares of KaloBios Pharmaceuticals (NASDAQ:KBIO) saw unusually-high trading volume on Tuesday , MarketBeat.Com reports. Approximately 79,387 shares traded hands during mid-day trading, a decline of 3% from the previous session’s volume of 81,564 shares.The stock last traded at $2.14 and had previously closed at $2.12. Separately, Zacks raised KaloBios Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, May 15th. The company’s market cap is $8.70 million. The company has a 50 day moving average price of $2.21 and a 200 day moving average price of $3.70. KaloBios Pharmaceuticals (NASDAQ:KBIO) last posted its quarterly earnings data on Monday, August 10th. The company reported ($1.46) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.68) by $0.22. Equities analysts predict that KaloBios Pharmaceuticals will post ($6.49) earnings per share for the current year. KaloBios Pharmaceuticals, Inc., is a United States-based company, which develops protein therapeutics. The Company develops and engineers antibodies and protein therapeutics. Its monoclonal antibodies (NASDAQ:KBIO) technology that is being used for reengineering antibodies with products being developed in the areas of infectious disease, autoimmunity, and oncology. Its suite of technologies can also be used for discovery and engineering of other proteins, industrial enzymes and small molecule drugs. It conducts three clinical development programs in leukemia, infectious diseases, and autoimmune diseases. http://sleekmoney.com/kalobios-pharmaceuticals-sees-large-vo… Gruß C. |
|
| aus der Diskussion: | KaloBios Pharmaceuticals Inc. KBIO |
| Autor (Datum des Eintrages): | centgreifer (03.09.15 19:04:15) |
| Beitrag: | 73 von 85 (ID:50552933) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |